Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer

被引：4
|
作者：
Kumar, Rachit [1 ]
Jabbour, Salma K. [2 ]
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[2] Rutgers State Univ, Robert Wood Johnson Med Sch, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA
来源：
JOURNAL OF RADIATION ONCOLOGY | 2013年 / 2卷 / 04期
关键词：
Pancreatic cancer; Neoadjuvant therapy; Radiation therapy; Resectable; Borderline resectable;
D O I：
10.1007/s13566-013-0120-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Neoadjuvant chemoradiation for resectable and borderline resectable pancreatic cancer has been widely investigated in the past two decades. Research demonstrates that this therapy may help improve surgical margins, reduce rates of lymph node positivity, allow for earlier initiation of systemic therapy, and select for patients with aggressive disease in whom surgery may not be warranted. This review presents the data for neoadjuvant chemoradiation in pancreatic cancer with a focus on resectable and borderline resectable disease.
引用
收藏
页码：353 / 367
页数：15
相关论文
共 50 条
  • [21] Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
    Danko Mikulic
    Anna Mrzljak
    [J]. World Journal of Clinical Cases, 2021, 9 (20) : 5398 - 5407
  • [22] Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    Peng, June S.
    Wey, Jane
    Chalikonda, Sricharan
    Allende, Daniela S.
    Walsh, R. Matthew
    Morris-Stiff, Gareth
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (04) : 373 - 378
  • [23] Toxicity associated with neoadjuvant therapy for borderline resectable pancreatic cancer (BRPC).
    Beg, M. S.
    Olowokure, O. O.
    Ali, S.
    Ahmad, S. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
    Mikulic, Danko
    Mrzljak, Anna
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (20) : 5398 - 5407
  • [25] Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    Stefan Heinrich
    [J]. Hepatobiliary & Pancreatic Diseases International, 2019, 18 (04) : 305 - 306
  • [26] Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    Heinrich, Stefan
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (04) : 305 - 306
  • [27] Neoadjuvant Chemoradiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
    Shafi, S.
    Kaubisch, A.
    [J]. PANCREAS, 2015, 44 (08) : 1413 - 1413
  • [28] Early outcomes following neoadjuvant therapy for borderline resectable pancreatic cancer
    Goody, R.
    Arunsingh, M.
    Murray, L.
    Adair, R.
    Albazaz, R.
    Anthoney, A.
    Beckett, C.
    Cairns, A.
    Collinson, F.
    Guthrie, A.
    Kenyon, A.
    Macutkiewicz, C.
    Sanni, L.
    Sheridan, M.
    Smith, A.
    Trainor, P.
    Radhakrishna, G.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S776 - S777
  • [29] Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
    Nichols, Romaine Charles
    Rutenberg, Michael
    [J]. WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2019, 11 (07): : 303 - 307
  • [30] Neoadjuvant fractionated versus hypofractionated chemoradiotherapy in resectable and borderline resectable pancreatic cancer
    Lee, Darren
    Nelson, Bailey
    Rai, Shesh
    Rai, Jayesh
    Wang, Kyle
    Sohal, Davendra
    Olowokure, Olugbenga Olanrele
    Rojan, Adam
    Patel, Sameer H.
    Wilson, Gregory
    Ahmad, Syed A.
    Kharofa, Jordan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345